June 29, 2022

Medical Trend

Medical News and Medical Resources

CDKN2A/2B gene mutation organoid pharmacological model

CDKN2A/2B gene mutation organoid pharmacological model


CDKN2A/2B gene mutation organoid pharmacological model.   It is generally believed that CDKN2A/2B gene loss-of-function mutations may cause abnormal activation of CDK2/4/6, so CDK inhibitors may be used as a potential treatment for patients with CDKN2A/2B mutations.

CDKN2A/2B are tumor suppressor genes, both located on chromosome 9, encoding p16CDKN2A and p15INK4B proteins respectively, which can inhibit the activity of CDK kinase and regulate the G1 cell cycle. The inactivation of CDKN2A/2B may lead to uncontrolled cell growth and proliferation, leading to cancer [1]. (Picture 1 / Picture 2)

 

CDKN2A/2B gene mutation organoid pharmacological model
Figure 1. CDKN2A/2B regulates the cell cycle (AleaA. Mills, Nature Review Cancer, 2010)

 

CDKN2A/2B is the most common somatic mutation gene in metastatic tumors. Deletions, mutations or hypermethylation often occur in many tumors, including head and neck tumors, non-small cell lung cancer, prostate cancer, glioma, esophageal squamous cell carcinoma, Bladder cancer and T-cell lymphoma, among which CDKN2A is considered to be the second most frequently inactivated gene in cancer after p53.

 

CDKN2A/2B gene mutation organoid pharmacological model

Figure 2. Epigenetic regulation of CDKN2A/2B expression (AleaA. Mills, Nature Review Cancer, 2010)

 

It is generally believed that CDKN2A/2B gene loss-of-function mutations may cause abnormal activation of CDK2/4/6, so CDK inhibitors may be used as a potential treatment for patients with CDKN2A/2B mutations. One study based on melanoma cell lines supports this hypothesis. The results of the study indicate that CDKN2A methylation, mutation or p16(INK)(4A) protein loss is associated with increased sensitivity to CDK4/6 inhibitor Palbociclib [2]. But in another study, for patients with imatinib/sunitinib-resistant gastrointestinal stromal tumors (GIST) who lacked P16/CDKN2A, pabocillin monotherapy was not effective [3].

 

Pabocillin has been approved for marketing in ER-positive Her2-negative breast cancer, and its application in other tumor indications, especially the study of co-administration, is becoming a hot spot. Therefore, the development of CDKN2A/2B gene mutation therapy drugs and the study of co-administration have always been a hot spot for medical researchers.

 

At present, Ketu Medical has successfully constructed a tumor organoid model containing a variety of driving target mutations and somatic mutations by simulating the tumor growth microenvironment. The series of products including CDKN2A/2B gene mutations are as follows (see Table 1):

Table 1 Information on CDKN2A/2B gene mutation model of Ketu Medicine

CAT#Clinical case diagnosisCDKN2A/2B MutationOther Pathogenic Mutation
KO-73325Pancreatic cancer lung metastasisCDKN2A H83RKRAS G12D /TP53 c.241dup p.T81Nfs*68/ALK-HEPACAM2 Fusion
KO-59933Lung cancerCDKN2A G45RFGFR4 amplification
KO-58075Esophageal cancerCDKN2A V115LTP53 R249G / TP53 G245D
KO-65478Stomach cancerCDKN2A R80*XPO1 E571K / XPO1 E571K
KO-41723Bladder CancerCDKN2A/CDKN2B DeletionSPTA1 .G505R/PIK3CA E545K/FGFR3 Y373C/FOXO1 P519L/MED12 G44D
KO-46617Pancreatic cancerCDKN2A/CDKN2B DeletionKRAS G12V/TP53 V203E
KO-4306 0Esophageal cancerCDKN2A/CDKN2B DeletionPIK3CA Q546K/ STK11 P294L/
KO-96253Lung cancerCDKN2A/CDKN2B DeletionEGFR L858R/ EGFR /MET/MYC/CCND1/CDK6 amplification

Related Services

 

  • Organoid model construction service
  • Organoid model identification related testing services
  • Cell drug efficacy testing service
  • Drug synergy testing service
  • PDOX mouse model in vivo drug efficacy testing service

 

 

 

 

 

(source:internet, reference only)


Disclaimer of medicaltrend.org